TY - JOUR
T1 - Biological pathways and genetic variables involved in pain
AU - Shi, Qiuling
AU - Cleeland, Charles S.
AU - Klepstad, Pål
AU - Miaskowski, Christine
AU - Pedersen, Nancy L.
AU - AUTHOR GROUP
AU - Abernethy, Amy P.
AU - Baas, Frank
AU - Barsevick, Andrea M.
AU - Bartels, Meike
AU - Boomsma, Dorret I.
AU - Chauhan, Cynthia
AU - Dueck, Amylou C.
AU - Frost, Marlene H.
AU - Hall, Per
AU - Halyard, Michele Y.
AU - Martin, Nicholas G.
AU - Mosing, Miriam
AU - Movsas, Benjamin
AU - van Noorden, Cornelis J. F.
AU - Patrick, Donald L.
AU - Ropka, Mary E.
AU - Shinozaki, Gen
AU - Singh, Jasvinder A.
AU - Sloan, Jeff A.
AU - Sprangers, Mirjam A. G.
AU - Veenhoven, Ruut
AU - Yang, Ping
AU - Zwinderman, Ailko H.
PY - 2010
Y1 - 2010
N2 - Purpose This paper summarizes current knowledge of pain-related and analgesic-related pathways as well as genetic variations involved in pain perception and management. Methods The pain group of the GENEQOL Consortium was given the task of summarizing the current status of research on genetic variations in pain and analgesic efficacy. This review is neither exhaustive nor comprehensive; we focus primarily on single-nucleotide polymorphisms. Results Two categories of potential genetic pain-perception pathways were identified: neurotransmission modulators and mechanisms that affect inflammation. Four categories were identified for analgesic efficacy: genes related to receptor interaction, modulation of opioid effects, metabolism, and transport. Various genetic variations involved in these pathways are proposed as candidate genetic markers for pain perception and for individual sensitivity to analgesics. Conclusions Candidate gene association studies have been used to provide evidence for the genetic modulation of pain perception and response to analgesics. However, the nature and range of genetic modulation of pain is not well addressed due to the limited number of patients and the limited number of genes and genetic variants investigated in studies to date. Moreover, personalized analgesic treatments will require a more complete understanding of the effects of genetic variants and gene-gene interactions in response to analgesics
AB - Purpose This paper summarizes current knowledge of pain-related and analgesic-related pathways as well as genetic variations involved in pain perception and management. Methods The pain group of the GENEQOL Consortium was given the task of summarizing the current status of research on genetic variations in pain and analgesic efficacy. This review is neither exhaustive nor comprehensive; we focus primarily on single-nucleotide polymorphisms. Results Two categories of potential genetic pain-perception pathways were identified: neurotransmission modulators and mechanisms that affect inflammation. Four categories were identified for analgesic efficacy: genes related to receptor interaction, modulation of opioid effects, metabolism, and transport. Various genetic variations involved in these pathways are proposed as candidate genetic markers for pain perception and for individual sensitivity to analgesics. Conclusions Candidate gene association studies have been used to provide evidence for the genetic modulation of pain perception and response to analgesics. However, the nature and range of genetic modulation of pain is not well addressed due to the limited number of patients and the limited number of genes and genetic variants investigated in studies to date. Moreover, personalized analgesic treatments will require a more complete understanding of the effects of genetic variants and gene-gene interactions in response to analgesics
U2 - https://doi.org/10.1007/s11136-010-9738-x
DO - https://doi.org/10.1007/s11136-010-9738-x
M3 - Article
C2 - 20842532
SN - 0962-9343
VL - 19
SP - 1407
EP - 1417
JO - Quality of life research
JF - Quality of life research
IS - 10
ER -